Eleven biologics have been approved for psoriasis in Japan, targeting TNF-α (adalimumab [ADA], infliximab [IFX], certolizumab pegol [CZP]), IL-17 (ixekizumab [IXE], secukinumab [SEC], brodalumab [BRO], bimekizumab), and IL-23 (ustekinumab [UST], guselkumab [GUS], risankizumab [RIS], and tildrakizumab). Here, IL23A is linked to psoriasis.